Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emergent Biosolutions (EBS) has issued an announcement.
Emergent BioSolutions Inc.’s subsidiary sold its global rights to the RSDL® decontamination lotion and its subsidiary EPPU to SERB Pharmaceuticals, including all related assets and intellectual property. The $75 million deal, with a potential additional $5 million milestone payment, also transfers certain government contracts to SERB, including one with the U.S. Department of Defense. Post-sale, Emergent will not compete in the chemical decontamination space for three years and will continue to manufacture the lotion for SERB under a long-term agreement, ensuring a smooth transition.
Find detailed analytics on EBS stock on TipRanks’ Stock Analysis page.